Inclusion body myositis
ORPHA:611DiseaseNot applicableAdult, Elderly
Фенотипы (HPO)14
Очень частый (80–99%)10
HP:0002960Autoimmunity
HP:0003200Ragged-red muscle fibers
HP:0003202Skeletal muscle atrophy
HP:0003236Elevated circulating creatine kinase concentration
HP:0003457EMG abnormality
HP:0003701Proximal muscle weakness
HP:0003731Quadriceps muscle weakness
HP:0003805Rimmed vacuoles
HP:0004303Abnormal muscle fiber morphology
HP:0009071Inflammatory myopathy
Частый (30–79%)3
HP:0001315Reduced tendon reflexes
HP:0008872Feeding difficulties in infancy
HP:0034153Anti-cytosolic-5-nucleotidase-1A antibody positivity
Периодический (5–29%)1
HP:0003326Myalgia
Эпидемиология7
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 1 000 000 | 0.5 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 2.5 | Sweden | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.49 | Netherlands | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.2 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.1 | United States | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1 | Turkey | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.2 | Sweden | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)